Image Response Assessment Team (IRAT) Shared Resource PROJECT SUMMARY Radiology began as a discipline that specialized in the visualization of anatomy. In the context of cancer, modern technologies and innovations transformed imaging into a non-invasive tool that not only assesses solid tumor size and shape but also interrogates the spatial heterogeneity within tumors on the basis of their radiologic appearance, metabolism, and physiology. The overall goal of the Image Response Assessment Team (IRAT) Shared Resource is to enhance the scientific quality of clinical studies, by offering a single point of entry for Moffitt Cancer Center (MCC) members to access traditional and advanced quantitative image analysis services. To this end, efforts are organized around three Specific Aims, which are to: 1) maintain and improve the high reliability and fast turnaround times for RECIST (Response Evaluation Criteria in Solid Tumors) and other standard tumor assessment metrics; 2) improve therapeutic trials at MCC by translating research advances in radiomics and multi-parameter MRI (mpMRI) analyses into turnkey imaging biomarker services; and 3) provide members with access to non-traditional imaging endpoints for therapeutic trials. IRAT consists of five full-time staff and provides quantitative image-based tumor metrics to support investigator- initiated, cooperative group, and industry-sponsored clinical trials at MCC, and is part of the national consortium of Cancer Center IRATs. IRAT has essential roles in the MCC mission ?to contribute to the prevention and cure of cancer,? by providing the support and services necessary to integrate both traditional and innovative imaging endpoints into clinical trials and by providing quality assurance and control throughout the process to yield scientifically valid results. With rapid advances in treatment paradigms such as immunotherapies, IRAT provides improved imaging endpoints to meet the needs of these cutting-edge studies of MCC members. IRAT has witnessed sustained increases in the volume of quantitative image response assessment services provided. A total of 298 new trials requiring imaging response assessment were activated in FY11-15, rising from 39 in FY11 to 65 in FY15. Developing an infrastructure for IRAT has permitted the pursuit of other funded trial opportunities that use advanced and/or investigational imaging techniques, analyses, and novel biomarkers. For example, IRAT is supporting multiple grant applications and funded projects by members investigating radiomic and mpMRI imaging biomarkers in retrospective and prospective clinical and pre-clinical studies. During the past project period, IRAT served 34 members from 4 MCC Programs. Overall usage by members was 94%, with 63% of total usage supporting members with peer- reviewed funding. IRAT-supported studies resulted in a total of 62 peer-reviewed scientific publications during this period.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
H. Lee Moffitt Cancer Center & Research Institute
United States
Zip Code
Schaal, Courtney M; Bora-Singhal, Namrata; Kumar, Durairaj Mohan et al. (2018) Regulation of Sox2 and stemness by nicotine and electronic-cigarettes in non-small cell lung cancer. Mol Cancer 17:149
Zhu, Genyuan; Brayer, Jason; Padron, Eric et al. (2018) OMIP-049: Analysis of Human Myelopoiesis and Myeloid Neoplasms. Cytometry A 93:982-986
Bowman-Curci, Meghan; Quinn, Gwendolyn P; Reinecke, Joyce et al. (2018) Comparing fertility preservation resources and policies between NCCN member and non-member institutions. Support Care Cancer :
Hampras, Shalaka S; Locke, Frederick L; Chavez, Julio C et al. (2018) Prevalence of cutaneous viral infections in incident cutaneous squamous cell carcinoma detected among chronic lymphocytic leukemia and hematopoietic stem cell transplant patients. Leuk Lymphoma 59:911-917
Kim, Youngchul; Pierce, Christine M; Robinson, Lary A (2018) Impact of viral presence in tumor on gene expression in non-small cell lung cancer. BMC Cancer 18:843
Persi, Erez; Duran-Frigola, Miquel; Damaghi, Mehdi et al. (2018) Systems analysis of intracellular pH vulnerabilities for cancer therapy. Nat Commun 9:2997
Rosenberger, Albert; Hung, Rayjean J; Christiani, David C et al. (2018) Genetic modifiers of radon-induced lung cancer risk: a genome-wide interaction study in former uranium miners. Int Arch Occup Environ Health 91:937-950
Chen, Yan; Zhu, Jin-Yi; Hong, Kwon Ho et al. (2018) Structural Basis of ALDH1A2 Inhibition by Irreversible and Reversible Small Molecule Inhibitors. ACS Chem Biol 13:582-590
Kahen, Elliot John; Brohl, Andrew; Yu, Diana et al. (2018) Neurofibromin level directs RAS pathway signaling and mediates sensitivity to targeted agents in malignant peripheral nerve sheath tumors. Oncotarget 9:22571-22585
Hoffman, Melissa A; Fang, Bin; Haura, Eric B et al. (2018) Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer. J Proteome Res 17:63-75

Showing the most recent 10 out of 1254 publications